Initial Treatment Strategies for Bronchiectasis and NTM Pulmonary Disease

In this episode, host Doreen Addrizzo-Harris, MD, FCCP, is joined by Keren Bakal, MD, and Amy Springer, MSN, FNP-C, to explore initial treatment strategies for bronchiectasis and nontuberculous mycobacteria (NTM) pulmonary disease. The conversation delves into the critical role of airway clearance therapy, challenges in selecting individualized treatments, and the importance of patient education. The experts also discuss the latest guidelines for managing nodular and cavitary NTM lung disease, including when to initiate treatment vs monitoring, as well as strategies for managing common drug toxicities. Additionally, they examine comorbidities often seen in patients with bronchiectasis, such as gastrointestinal disorders, sinus disease, and psychosocial factors like anxiety and depression. This episode is part of CHEST's Bridging Specialties®: Timely Diagnosis for NTM Disease and Bronchiectasis program. LEARN MORE » This program is produced in partnership with CHEST and is sponsored by Insmed Incorporated.   HOST Doreen J. Addrizzo-Harris, MD, FCCP Fiona and Stanley Druckenmiller Professor of Pulmonary, Critical Care, and Sleep Medicine  Director, NYULH Bronchiectasis and NTM Clinical and Translational Program NYU Grossman School of Medicine New York, NY   PANELISTS Keren Bakal, MD Clinical Attending, Pulmonary and Critical Care Medicine Overlook Medical Center/Atlantic Health System Summit Health Livingston, NJ   Amy Springer, MSN, FNP-C Senior Nurse Practitioner NYULH Bronchiectasis and NTM Clinical and Translational Program  Division of Pulmonary, Critical Care, and Sleep Medicine  NYU Langone Health  New York, NY 

There are no comments yet.

Please log in to write the first comment.